GUFICBIO — Gufic Biosciences Income Statement
0.000.00%
Last trade - 00:00
- IN₹29.74bn
- IN₹33.16bn
- IN₹6.91bn
- 49
- 11
- 77
- 40
2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,508 | 3,788 | 4,877 | 7,792 | 6,906 |
Cost of Revenue | |||||
Gross Profit | 1,469 | 1,806 | 2,155 | 3,376 | 3,264 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,094 | 3,403 | 4,201 | 6,506 | 5,753 |
Operating Profit | 413 | 385 | 676 | 1,286 | 1,153 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 353 | 301 | 577 | 1,268 | 1,067 |
Provision for Income Taxes | |||||
Net Income After Taxes | 219 | 227 | 442 | 958 | 797 |
Net Income Before Extraordinary Items | |||||
Net Income | 219 | 227 | 442 | 958 | 797 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 219 | 227 | 442 | 958 | 797 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.82 | 2.34 | 4.56 | 9.88 | 8.22 |
Dividends per Share |